TNG462 + RMC-9805 + RMC-6236 + mFOLFIRINOX + gemcitabine/nab-paclitaxel
Phase 1/2Recruiting 0 watching 0 views this week💤 Quiet
38
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
PDAC
Conditions
PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC, RAS Mutation, MTAP Deletion, Lung Cancer, Pancreatic Cancer Metastatic, Thoracic Cancer
Trial Timeline
May 31, 2025 → Dec 1, 2027
NCT ID
NCT06922591About TNG462 + RMC-9805 + RMC-6236 + mFOLFIRINOX + gemcitabine/nab-paclitaxel
TNG462 + RMC-9805 + RMC-6236 + mFOLFIRINOX + gemcitabine/nab-paclitaxel is a phase 1/2 stage product being developed by REVOLUTION Medicines for PDAC. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06922591. Target conditions include PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC.
Hype Score Breakdown
Clinical
13
Activity
8
Company
7
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06922591 | Phase 1/2 | Recruiting |
Competing Products
4 competing products in PDAC
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pembrolizumab + Defactinib | Merck | Phase 2 | 52 |
| Pumitamig + Nab-paclitaxel + Gemcitabine + mFOLFIRINOX | Bristol Myers Squibb | Phase 2 | 51 |
| Nivolumab + CCR2/CCR5 dual antagonist + GVAX | Bristol Myers Squibb | Phase 1/2 | 40 |
| Cemiplimab Plus Gemcitabine | Regeneron Pharmaceuticals | Phase 2 | 51 |
Other Products from REVOLUTION Medicines
daraxonrasibPhase 3
74
daraxonrasib + docetaxelPhase 3
74
RMC-6236 + Gemcitabine + nab-paclitaxel + Irinotecan + Liposomal irinotecan + 5-fluorouracil + leucovorin + OxaliplatinPhase 3
74
RMC-6291 + RMC-6236 + Pembrolizumab + Cisplatin + Carboplatin + Pemetrexed + RMC-9805Phase 1/2
38
Elironrasib + DaraxonrasibPhase 1/2
38